|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-8
|
|
pubmed:abstractText |
Vanilloid receptor TRPV1 is a cation channel that can be activated by a wide range of noxious stimuli, including capsaicin, acid, and heat. Blockade of TRPV1 activation by selective antagonists is under investigation by several pharmaceutical companies in an effort to identify novel agents for pain management. Here we report that replacement of substituted benzyl groups by an indan rigid moiety in a previously described N-indazole- N'-benzyl urea series led to a number of TRPV1 antagonists with significantly increased in vitro potency and enhanced drug-like properties. Extensive evaluation of pharmacological, pharmacokinetic, and toxicological properties of synthesized analogs resulted in identification of ( R)-7 ( ABT-102). Both the analgesic activity and drug-like properties of ( R)-7 support its advancement into clinical pain trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:BayburtErol KEK,
pubmed-author:FaltynekConnie RCR,
pubmed-author:GomtsyanArthurA,
pubmed-author:HannickSteven MSM,
pubmed-author:HonorePriscaP,
pubmed-author:JarvisMichael FMF,
pubmed-author:LeeChih-HungCH,
pubmed-author:MarshKennan CKC,
pubmed-author:McDonaldHeath AHA,
pubmed-author:SchmidtRobert GRG,
pubmed-author:SullivanJames PJP,
pubmed-author:SurowyCarol SCS,
pubmed-author:WetterJill MJM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
14
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
392-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18183945-Administration, Oral,
pubmed-meshheading:18183945-Analgesics,
pubmed-meshheading:18183945-Animals,
pubmed-meshheading:18183945-Biological Availability,
pubmed-meshheading:18183945-Dogs,
pubmed-meshheading:18183945-Haplorhini,
pubmed-meshheading:18183945-Humans,
pubmed-meshheading:18183945-Indazoles,
pubmed-meshheading:18183945-Indenes,
pubmed-meshheading:18183945-Microsomes, Liver,
pubmed-meshheading:18183945-Pain,
pubmed-meshheading:18183945-Rats,
pubmed-meshheading:18183945-Stereoisomerism,
pubmed-meshheading:18183945-Structure-Activity Relationship,
pubmed-meshheading:18183945-TRPV Cation Channels,
pubmed-meshheading:18183945-Urea
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.
|
|
pubmed:affiliation |
Global Pharmaceutical Research and Development, Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064, USA. arthur.r.gomtsyan@abbott.com
|
|
pubmed:publicationType |
Journal Article,
In Vitro
|
